phase 1 clinical trial
Showing 1 - 25 of >10,000
Safety, Tolerability, Pharmacokinetics Trial in Karachi (RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets))
Completed
- Safety
- +2 more
- RHN-001 (one tablet 750mg)
- RHN-001 (750mg * 2 Tablets)
-
Karachi, Sindh, PakistanCenter for Bioequivalence Studies and clinical research (CBSCR),
Apr 26, 2023
Healthy Subjects Trial in SEoul (C1K, Placebo)
Recruiting
- Healthy Subjects
- C1K
- Placebo
-
SEoul, Korea, Republic ofSeoul National University Clinical Trial Center
Aug 3, 2023
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma Trial in Miami (Lenvatinib, Pembrolizumab, Hypofractionated
Not yet recruiting
- Recurrent Endometrial Carcinoma
- Unresectable Endometrial Carcinoma
- Lenvatinib
- +2 more
-
Miami, FloridaUniversity of Miami
Jan 10, 2023
Healthy Adult Subjects Trial in Seoul (ID110521156, Placebo of ID110521156)
Not yet recruiting
- Healthy Adult Subjects
- ID110521156
- Placebo of ID110521156
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 26, 2023
Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Tianjin (NTQ2494 tablet)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- NTQ2494 tablet
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 17, 2023
Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- SKG0106
-
Katy, Texas
- +1 more
Aug 15, 2023
SARS-CoV-2 Infection Trial in Hangzhou (Placebo, COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10
Recruiting
- SARS-CoV-2 Infection
- Placebo
- +4 more
-
Hangzhou, Zhejiang, ChinaShulan (Hangzhou) Hospital
Nov 7, 2023
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Trial (COVAC-1, Saline Placebo)
Not yet recruiting
- Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- COVAC-1
- Saline Placebo
- (no location specified)
Jan 23, 2023
Solid Tumor, Colorectal Cancer, Sigmoid Colon Cancer Trial in Seoul (GB104(Level 1), GB104(Level 2), GB104(Level 3))
Recruiting
- Solid Tumor
- +5 more
- GB104(Level 1)
- +2 more
-
Seoul, Gangnam-gu, Korea, Republic ofSamsung Medical Center
Jul 5, 2023
Healthy Trial (DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg)
Not yet recruiting
- Healthy
- DA-8010 5mg
- +2 more
- (no location specified)
Aug 11, 2023
Safety and Tolerability Trial in Shanghai (JMKX003142 will be administered orally, Placebo in Cohorts 1 to 7, Placebo in 3
Recruiting
- Safety and Tolerability
- JMKX003142 will be administered orally
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Oct 13, 2023
Healthy Trial (763SIP8/MPLA-5 vaccine)
Not yet recruiting
- Healthy
- 763SIP8/MPLA-5 vaccine
- (no location specified)
Mar 15, 2023
Malaria Trial in Lambaréné (Vaccine AnAPN1)
Not yet recruiting
- Malaria
- Vaccine AnAPN1
-
Lambaréné, Moyen- Ogooué, GabonCentre de Recherches Médicales de Lammbaréné
Jun 21, 2023
Severe Traumatic Brain Injury, Intracranial Hypertension Trial in Fort Sam Houston, San Antonio (External Lumbar drainage)
Not yet recruiting
- Severe Traumatic Brain Injury
- Intracranial Hypertension
- External Lumbar drainage
-
Fort Sam Houston, Texas
- +1 more
Jun 3, 2023
Healthy Trial in Ciudad de México (Tirfostina/L-Carnitina)
Enrolling by invitation
- Healthy
- Tirfostina/L-Carnitina
-
Ciudad de México, Azcapotzalco, MexicoPharmet, S.A de C.V.
Aug 2, 2022
Healthy Trial in Seoul (ID120040002, Compound-X, Placebo comparator)
Recruiting
- Healthy
- ID120040002
- +2 more
-
Seoul, Korea, Republic ofSeoul National University Hospital
Dec 21, 2022
Healthy Trial in Soeul (DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg)
Not yet recruiting
- Healthy
- DA-8010 5mg
- +2 more
-
Soeul, Korea, Republic ofSeoul National University Hospital
Aug 7, 2023
T-lymphoblastic Lymphoma, T-ALL Trial in Shanghai (CAR-T)
Recruiting
- T-lymphoblastic Lymphoma
- T-ALL
- CAR-T
-
Shanghai, ChinaShanghai Ruijin Hospital
Nov 14, 2023
HIV-1-infection Trial in Amsterdam (ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes)
Active, not recruiting
- HIV-1-infection
- ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
-
Amsterdam, Noord-Holland, NetherlandsAmsterdam University Medical Centers, location AMC
Jan 31, 2023